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ABSTRACT
The downregulation of the DNA damage response
(DDR) enables aggressive tumors to achieve uncon-
trolled proliferation against replication stress, but the
mechanisms underlying this process in tumors are
relatively complex. Here, we demonstrate a mecha-
nism through which a distinct E3 ubiquitin ligase,
ITCH, modulates DDR machinery in triple-negative
breast cancer (TNBC). We found that expression of
a nuclear form of ITCH was significantly increased
in human TNBC cell lines and tumor specimens.
Phosphorylation of ITCH at Ser257 by AKT led to
the nuclear localization of ITCH and ubiquitination of
H1.2. The ITCH-mediated polyubiquitination of H1.2
suppressed RNF8/RNF168-dependent formation of
53BP1 foci, which plays important roles in DDR. Con-
sistent with these findings, impaired ITCH nuclear
translocation and H1.2 polyubiquitination sensitized
cells to replication stress and limited cell growth and
migration. AKT activation of ITCH-H1.2 axis may con-
fer TNBC cells with a DDR repression to counteract
the replication stress and increase cancer cell sur-
vivorship and growth potential.
INTRODUCTION
Breast cancer (BC) is the most frequently diagnosed type
of cancer in women worldwide (1). Approximately 30%
of women initially diagnosed with early-stage disease will
ultimately develop metastatic lesions, and nearly half of
all BC patients develop distant metastatic disease after
chemotherapeutic and/or hormonal agent treatment (2).
Unfortunately, current clinical strategies fail to adequately
treat metastatic disease, and the mechanisms underlying BC
metastases remain poorly understood.
Patients with basal-like triple-negative BC (TNBC), the
most aggressive BC subtype (1), have high rates of recur-
rence and distant metastases, which exhibit high levels of
DNA replication stress (3). DNA replication stress and
DNA damage induce the formation of aberrant DNA struc-
tures that trigger the DNA damage response (DDR) sig-
naling pathway (4,5). DDR typically leads either to DNA
repair, or in the case of irreparable damage, to apopto-
sis or senescence (6,7). When oncogenes induce persistent
DNA replication stress, high mutation rates, and severe ge-
nomic instability; tumor cells may downregulate or acquire
faulty DDR mechanisms through genetic and epigenetic al-
terations that support continued survival despite of poten-
tial genomic damage (6,7). Thus, the dysregulation of genes
that encoding DDR machinery and genes involved in DNA
repair have been associated with tumor development, pro-
gression, metastasis, malignancy grade, and patient prog-
nosis and survival across many cancers (4,5,8,9). Therefore,
interventions to restore DDR signaling to promote tumor
cell death could potentially serve as efficacious cancer ther-
apies.
In response to DNA damage, such as double strand
breaks (DSBs), histone H2AX is phosphorylated (to
H2AX) by PI3K-like kinases (PIKKs), which initiates the
recruitment of many DDR factors, such as MDC1, which
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activate cell cycle checkpoints and DDR and can serve
as scaffold proteins for the recruitment other downstream
DDR factors (2,3,6). The ubiquitin (Ub)-dependent DNA
damage signaling cascade is an important regulatory mech-
anism of the DDR (10). Polyubiquitinated histone H1 was
recently shown to serve as an important signaling interme-
diate for the DSB repair process that depends on the E3
Ub ligases RNF8 and RNF168 (11,12). Whether the activ-
ity of polyubiquitinated histone H1 and RNF8/RNF168-
dependent DDR events are negatively regulated in aggres-
sive tumors, however, has not yet been explored.
ITCH is a member of the E6-AP carboxyl terminus
(HECT) subfamily of E3 Ub ligases (10). ITCH ubiqui-
tination (Ubn) controls distinct physiological processes in
normal cells, including DDR, T-cell differentiation, the im-
mune response, and cell death (13,14). ITCH gene copy
numbers are amplified in anaplastic thyroid carcinoma (15)
and in several other human malignancies, including BC, ac-
cording to the Oncomine database. In the current study, we
provide the first evidence that ITCH can function as an
epigenetic regulator of the DDR that is overexpressed in
BC cell lines and tumors. We define a mechanism through
which poly-Ubn of H1.2 by nuclear AKT-activated ITCH
suppresses cellular DDR signaling to counteract replication
stress in TNBC cells. The PI3K/AKT pathway is a ma-
jor pathway that leads to tumor proliferation in BC (16).
Aberrant activation of this pathway, which occurs due to
loss of the lipid phosphatase PTEN or activating muta-
tions in the PIK3CA gene, was identified in a large series of
TNBC patient samples (17). AKT activation of ITCH may
confer TNBC cells with a DDR repression mechanism to
counteract the replication stress constitutively induced by
PI3K/AKT signaling, thus increasing cancer cell survivor-
ship and growth potential. Tumor invasion and metastasis
are direct causes of cancer mortality and represent the cen-
tral clinical challenge of solid tumor oncology. Mapping the
signaling cascades essential to the metastatic program, such
as the PI3K/AKT/ITCH/H1.2 pathway, will enable the de-
velopment of more efficient treatment options.
MATERIALS AND METHODS
Human clinical samples
Tissue microarrays (TMAs) of 282 invasive BC cases with
clinical data, including ER/PR/HER2 status, grades, and
stages, were collected from resected breast tumors of pa-
tients with informed consent and institutional IRB approval
from the Markey Cancer Center Biospecimen Tissue and
Procurement Shared Resource Facility (P30CA177558) at
the University of Kentucky, Lexington. TMAs contain-
ing 100 cases of BC with normal tissue control speci-
mens (BR1002a) and 50 cases of invasive ductal carci-
noma and matched metastatic invasive ductal carcinoma of
lymph nodes from breast (BR1005) were purchased from
US Biomax, Inc.
Cell culture
HEK293T cells were maintained in DMEM containing
10% fetal bovine serum with antibiotic/antimycotic solu-
tion (Invitrogen). BC cell lines were cultured according
to the manufacturer’s protocol (ATCC). To establish sta-
ble knockdown of ITCH, stable clones of MDA-MB-231
cells transfected with ITCH shRNA were selected with
puromycin (300 ng/ml) for 4 weeks. MDA-MB-231 clones
with stable expression of GFP-tagged WT ITCH, S257A
ITCH, WT-H1.2 or K46R-H1.2 were selected with G418 (3
mg/ml). To establish luciferase-transfected MDA-MB-231
stable cells, cells were transduced with 2 × 107 lentiviral par-
ticles expressing firefly luciferase (Amsbio). Blasticidine (10
mg/ml) was added to select stably transduced cells. Max-
imum luciferase activity was detected using a microplate
spectrofluorometer (Molecular Devices).
Immunohistochemistry (IHC)
IHC was performed on tissue microarray (TMA) sections
using an anti-ITCH primary antibody (BD Biosciences,
1:100, 2 h, 37◦C) in the Pathology Core Laboratory at the
Beckman Research Institute of City of Hope. Staining was
visualized with 3,3′-diaminobenzidine (DAB) and hema-
toxylin counter staining. Digital images of IHC-stained
TMA slides were obtained at 40× magnification (0.0625
m2 per raw image pixel) using a Hamamatsu Nanozoomer
2.0-HT whole slide scanner and images were retrieved us-
ing NDP.view2 (Hamamatsu Photonics). ITCH expression
in each entire TMA spot was quantified by a visual grad-
ing system based on the extent of staining. All scoring was
performed by a single investigator blinded to the findings
regarding other pathological stains and patient outcome.
Only immunoreactivity in the nucleus was evaluated. Im-
munostaining for nuclear ITCH in each entire TMA spot
was graded as follows: negative, no staining of cells; low,
staining <5% of cells; medium, staining >5% and <50% of
cells; high, staining >50% of cells.
Immunoblotting (IB)
Cells were lysed in ice-cold buffer [150 mM NaCl, 10 mM
Tris–Cl pH 7.4, 5 mM EDTA, 1% Triton X-100] supple-
mented with protease inhibitors (Sigma-Aldrich). The pro-
tein concentration of each sample was quantified using the
Bio-Rad protein assay reagent (Cat#: 5000006, Bio-Rad).
For detection of histone and histone modify cations, to-
tal histones were isolated using the Histone Extraction Kit
(Cat#: ab113476, Abcam). Equal amounts of whole cell ex-
tracts or total histones were resolved by 4–15% or 15% SDS-
PAGE and immunoblotted with specified antibodies. To de-
tect the loading control including actin, GAPDH or histone
H3 the blot was stripped and reprobed with an indicated an-
tibody.
Immunofluorescence (IF) staining, microscopy and foci quan-
tification
Cells were grown on cover-slips (Fisherbrand, Cat #12-
545-80) in 6- or 24-well dishes, fixed for 10 min with 4%
paraformaldehyde, permeabilized for 10 min with PBS con-
taining 0.3% Triton X-100 (PBS-T), and blocked for 1 h in
5% bovine serum in PBS. Primary antibodies were diluted
in blocking buffer and incubated with fixed cells overnight
at 4◦C. Cells were washed and incubated with Alexa Fluor
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488-, 555-, or 685-conjugated goat anti-mouse or -rabbit
IgG (H+L) antibodies (Molecular Probes). Images were ac-
quired using an Axio Observer Inverted Microscope System
(Zeiss) or a laser scanning confocal microscope (Zeiss LSM
880 with Airyscan) in the Light Microscopy Digital Imag-
ing Core at the Beckman Research Institute of City of Hope.
For focus quantification experiments, nuclei were identi-
fied using the blue (4′,6-diamidino-2-phenylindole, DAPI)
channels and foci were imaged using the green (Alexa Fluor
488) or red (Alexa Fluor 555) channels. Focus counting
analysis was performed manually (by eye). To reduce po-
tential bias of the manual counting analysis, focus quan-
tification was validated by automatic counting using Im-
age Pro image analysis software (Media Cybernetics Inc.,
USA). Acquired objects were classified as foci when their
diameter was between 0.25 and 1.2 m. Foci bigger than 1.2
m were classified as clusters. Further cluster analysis was
performed by determining the cluster size and the estimated
number of foci contained within the area. For each sample,
30 to 100 cells were analyzed and different parameters, such
as the number of selected cells, average foci number/cell,
mean intensity, and number of foci-positive cells were cal-
culated. Cells with ≥ 5 foci were counted as H2AX focus-
positive cells, and the percentage of H2AX focus-positive
cells in the range of 30–100 DAPI-stained cells was cal-
culated. Data are presented for three independent experi-
ments.
Immunoprecipitation (IP)
Cells were lysed in buffer [50 mM Tris pH 7.5, 150 mM
NaCl, 1% Nonidet P-40, 1 mM EDTA, and protease in-
hibitors]. Total cell lysates (1 ml) were incubated with 1 g
antibodies overnight at 4◦C, followed by 2 h incubation with
50 l protein G-conjugated beads (Thermo Fisher Scien-
tific). Beads were washed with lysis buffer and the IP protein
complexes were analyzed by IB.
ITCH associated proteins analyzed by mass spectrometry
(MS)
MDA-MB-231 cells were lysed in buffer [20 mM Tris–
HCl, pH 7.3, 300 mM KCl, 0.2 mM EDTA, 0.5% Triton,
10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 mM
glycerophosphate, and 0.1 mM Na3VO4, and protease in-
hibitors]. Total protein (50 mg) was IP with anti-ITCH
(1:1000; BD Biosciences) or unspecific mouse monoclonal
IgG antibodies (I-1000; GeneTex Inc.) and 50 l protein G-
conjugated beads (Thermo Fisher), as above. Washed beads
were separated by SDS-PAGE. Following Coomassie Blue
Staining, protein bands were excised and digested. After
separation on a reversed phase LC column, eluted peptides
were analyzed on a MALDI-QIT-TOF-based mass spec-
trometer with electrospray ionization (Micromass/Waters).
The MS/MS data were processed using Masslynx soft-
ware (Micromass), and the MASCOT (Matrix Science)
search engine was used to search the NCBI non-redundant
database. Protein identifications were based on a minimum
random probability score of 25 and with a mass accuracy
of 0.1 Da.
Plasmids, mutagenesis, transfection, shRNA
Full-length human ITCH cDNA was amplified from hu-
man Hela cDNA and cloned into the pcDNA3.1 (Xpress-
tag, Invitrogen) and pET-32a(+) (Novagen) vectors. Ala
substitution at S257 of ITCH and Arg substitution at
K46 of H1.2 was performed using QuikChange II Site-
Directed Mutagenesis Kit (Agilent Technologies). WT
ITCH, S257A ITCH, WT H1.2, and K46R H1.2 cD-
NAs were cloned into pEGFP-C1 (Clontech), a gift from
Dr. Yanzhong Yang (City of Hope). ITCH deletion mu-
tants were generated by PCR and subcloned into Xpress-
tag pcDNA3.1. ITCH shRNA and scrambled control
shRNA were purchased from MISSION shRNA at Sigma-
Aldrich. HEK293T or MDA-MB-231 cells were trans-
fected using PolyJet DNA transfection Reagent (Signa-
Gen). DDK-tagged H1.2, H1.3 and H1.4 plasmids were
purchased from OriGene Technologies, Inc. pRK5-HA-
ubiquitin-K63, pRK5-HA-ubiquitin-K48, and pRK5-HA-
ubiquitin-K29 were purchased from Addgene.
Subcellular fractionation
HEK293T or breast cancer cells were washed with ice-cold
PBS, harvested by scraping or trypsinization, and collected
in a hypotonic lysis buffer [20 mM HEPES pH 7.0, 10 mM
KCl, 2 mM MgCl2, 0.5% NP-40, 1 mM Na3VO4, 1 mM
phenylmethylsulfonyl fluoride, and protease inhibitors] for
10 min on ice. Cells were homogenized by 20 strokes in a
tight-fitting Dounce homogenizer (Kontes disposable pes-
tle with microtubes, Fisher Scientific). After centrifugation
at 1300 × g, 4◦C, and 5 min to sediment nuclei, the super-
natant was transferred to a new tube and centrifuged at 13
000 × g for 20 min. The resulting supernatant was collected
as a cytoplasmic fraction and transferred to a prechilled
tube. The nuclear pellet was washed three times with hypo-
tonic lysis buffer, resuspended, and periodically vortexed in
nuclear extraction buffer [20 mM HEPES pH 7.9, 400 mM
NaCl, 1 mM EDTA pH 8.0, 1 mM EGTA pH 7.0 and pro-
tease inhibitors] on ice for 30 min. After centrifugation at 13
000 × g for 10 min at 4◦C, the nuclear lysates were collected
and transferred into prechilled tubes.
In vitro kinase assays
For kinase assays, endogenous kinase was IP from cells
using specific antibodies according to the published pro-
tocol (18). Protein substrates were added to protein G
conjugated-beads in buffer [25 mM MOPS pH 7.2, 12.5
mM -glycerol phosphate, 20 mM MgCl2, 12.5 mM MnCl2,
2 mM EDTA pH 8.0, 5 mM EGTA and 0.25 mM DTT],
with the addition of 20 mM ATP for cold reactions, and 10
mM ATP mixed with 10 Ci of [ -32P] ATP for radioac-
tive reactions. The reaction mixture was incubated at 37◦C
for 30 min, stopped by the addition of SDS loading buffer,
followed by SDS-PAGE. Phosphorylated proteins were de-
tected using autoradiography and protein levels were visu-
alized using Coomassie blue staining.
Generation of phospho-S257 ITCH antibody
Two peptides were used to generate a phospho-S257
(P-S257) ITCH antibody: C-SRPPRP(pS)RPPPPT-amide
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(phosphopeptide) and C-SRPPRPSRPPPPT-amide (non-
phosphopeptide). These sequences showed homology with
no other proteins but ITCH. The P-S257-ITCH antibody
was generated by Life Technologies.
MS analysis of ITCH phosphorylation by AKT
After in vitro phosphorylation by AKT, Coomassie blue-
stained ITCH recombinant protein was excised from the
gel. Gel fragments containing ITCH protein were subjected
to proteolysis with trypsin. The tryptic peptides were then
analyzed by nanoflow liquid chromatography tandem MS
(LC-MS/MS) on an Orbitrap Elite (Thermo Scientific) in-
terfaced with an EasyLC nano LC system using a self-
packed column (75 m × 150 mm; 3 m ReproSil-Pur
C18 beads, 120 Å, Dr Maisch GmbH) at a flow rate of
300 nl/min. The mass spectrometer was operated in data-
dependent mode with each full MS scan (m/z 350-1800)
followed by MS/MS for the 15 most intense ions with the
parameters: ≥+2 precursor ion charge, 1 Da precursor ion
isolation window, and 35 normalized collision energy of
CID. The precursor and fragment ions were analyzed at 60
000 and 15 000 resolutions, respectively, and searched with
Maxquant (version 1.5.1.0) against ITCH protein sequence
with Rattus as the species. Variable modifications allowed
were oxidation of M and phosphorylation S, T or Y. Data
were filtered at a 1% false discovery rate at protein, peptide
and phosphosite for high peptide confidence. The phospho-
peptide sequence and site localizations were confirmed by
manual inspection of the corresponding MS/MS spectra.
In vitro ubiquitination assays
In vitro ubiquitination assay was performed according to
the published protocol (19). Purified WT ITCH E3 ligase
and H1.2 substrates were incubated with E1, UbcH7 E2,
purified recombinant Itch-delta C2, and ubiquitin in reac-
tion buffer [25 mM Tris–HCl, 100 mM NaCl, 1 mM DTT,
2.5 mM ATP and 4 mM MgCl2]. After incubation for 90
min at 30◦C, the reactions were terminated by boiling in
SDS loading buffer and resolved by SDS-PAGE gel.
In vivo ubiquitination assay
In vivo ubiquitination assay was performed according to
the published protocol (20) with the following modifica-
tions: Briefly, 293T cells were transfected with his-ubiquitin
and other indicated plasmids for 36 h and harvested. To de-
tect HA-tagged proteins, cell pellets resuspended at 4◦C in
lysis buffer (50 mM Tris–HCl at pH 7.4, 150 mM NaCl,
1 mM EDTA, 1% Triton X-100) containing protease in-
hibitors and 5 mM NEM were disrupted by sonication
(2 × 10 s, 15% output, Virsonic 475 sonicator) and left
on ice for 30 min. Lysates were centrifuged at 10 000 ×
g for 5 min twice, and soluble protein was quantified by
BCA assay (Pierce). For immunoprecipitation of ubiquiti-
nated HA-H1.2, lysate protein (500 g) was diluted to 0.5
ml in RIPA buffer containing protease inhibitors. Lysates
were precleared with protein G-Sepharose (ThermoFisher)
beads for 1 h, and precleared supernatants were precipi-
tated with anti-HA (3F10, Sigma) or anti-DDK (Origene)
antibodies. Immune complexes recovered with protein G-
Sepharose were washed six times with RIPA buffer and
boiled in 6× sample buffer for 5 min. Denatured immune
complexes were analyzed by western blotting and detected
with antibodies to His (Cell Signaling) for Ubn. For detec-
tion of His-tagged ubiquitinated H1.2 species, 293T cells af-
ter transfection with the indicated plasmids for 36 h were
harvested by denaturing buffer A (6 M guanidine–HCl,
0.1 M Na2HPO4/NaH2PO4, 10 mM imidazole pH 8). Pre-
washed Ni-NTA agarose beads (QIAGEN) were incubated
with cell lysates for 3.5 h to pull down his-ubiquitin and his-
ubiquitin-conjugated proteins. Beads were then washed by
buffer A and buffer T1 (25 mM Tris–Cl, 20 mM Imidazole
pH 6.8) and analyzed by western blotting.
Comet assay
Single-cell gel electrophoretic comet assays were performed
following the manufacturer’s protocol (Enzo Life Sciences).
Briefly, MDA-MB-231 were collected, rinsed twice with ice-
cold PBS, combined with LM Agarose at 37◦C at a ratio of
1:10 (v/v), and immediately pipetted onto slides. For cell
lysis, the slides were immersed in pre-chilled Lysis Solu-
tion at 4◦C, for 30–60 min, then immersed in freshly pre-
pared Alkaline Solution, pH >13, for 20–60 min at room
temperature, in the dark. The slides were subjected to elec-
trophoresis at 15 V for 25 min (0.6 V/cm), and stained with
CYGREEN® Nucleic Acid Dye for 30 min. Images were
taken with a fluorescence microscope. Generally, a total of
50 cells in triplicate were analyzed per group. Comet tail
length was measured using an ocular micrometer and DNA
damage was calculated as: Comet tail length (M) = max-
imum total length - head diameter.
Purification of recombinant proteins
Full-length ITCH protein containing the C2 domain cannot
be expressed in bacteria. Therefore, the ITCH recombinant
proteins used in all experiments were truncated ITCH pro-
teins without the C2 domain. Truncated ITCH constructs
were generated by PCR as follows: ITCH (ITCH protein
with C2 domain deletion, aa 10–102), WW (four WW do-
mains, aa 326–511), HECT (HECT domain, aa 569–903).
ITCH deletion and S257A mutant plasmids were trans-
formed into BL21 (DE3)-competent cells (New England Bi-
olabs), and proteins were expressed with 0.3 mM isopropyl
bD-thiogalactopyranoside induction at 18◦C overnight and
purified according to the manufacturer’s protocol (No-
vagen). Briefly, the cell pellet was lysed in buffer [50 mM
tTis–Cl pH 7.5, 200 mM NaCl, 1.0% NP-40, 0.1% Na-
deoxycholate, and protease inhibitors] on ice for 30 min,
and the supernatant was collected by centrifugation at 11
000 × g for 10 min at 4◦C. His-tagged proteins were precip-
itated using Ni-nitrilotriacetic acid resins (Clontech) with
rotation at 4◦C for 1 h. The resins were washed three times
with lysis buffer and eluted with lysis buffer containing
150 mM imidazole. WT and K46R H1.2 proteins were ex-
pressed as HA-tagged recombinant proteins in 293T cells
and purified using affinity chromatography according to the
manufacturer’s protocol (Thermo Fisher Scientific). Protein
expression was confirmed by Coomassie blue staining and
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IB using anti-HA antibodies (1:1000) against HA-tag. Re-
combinant GST-tagged H1.2 proteins were purchased from
Novus Biologicals.
Nucleosome pull-down assays
HA-tagged WT or K46R H1.2 recombinant proteins be-
fore and after in vitro Ubn by ITCH were incubated with
nucleosomes containing purified and refolded histone oc-
tamers and biotinylated 601DNA (EpiCypher) in binding
buffer (20 mM HEPES, pH 7.9; 150 mM NaCl; 0.2 mM
EDTA, 10% glycerol; 0.1% NP40; 1 mM DTT and complete
protease inhibitors (Roche)) in the presence of streptavidin
agarose (Thermo Fisher Scientific) for 18 h at 40◦C. After
five washes in binding buffer, the beads were collected and
bound proteins were eluted in sample buffer and subjected
to immunoblot analysis.
Ionizing radiation (IR)
MDA-MB-231 cells were exposed to IR with total doses of
1 or 2 Gy using a CS-137 irradiator in the Animal Core Fa-
cility at the Beckman Research Institute of City of Hope.
Animal model of breast cancer
All animal experiments were approved by the Institutional
Animal Care and Use Committee at City of Hope and per-
formed in the Animal Core Facility at the Beckman Re-
search Institute of City of Hope. Female NSG mice, pur-
chased from the Jackson Laboratory were injected in the
fourth mammary fat pad with MDA-MB-231 cells (5 × 106
cells/0.1 ml in HBSS) transfected with a scrambled shRNA
(shControl) or shRNA targeting ITCH (shITCH) at the age
of 8–10 weeks. Tumor volumes were monitored and bio-
luminescent in vivo imaging was performed weekly start-
ing one week after tumor engraftment. Tumor volume was
calculated using the following formula: volume (mm3) =
a2 × b/2, where a is the tumor width in mm and b is the
tumor length in mm. Bioluminescent in vivo imaging was
monitored using a highly sensitive CCD camera mounted in
a light-tight specimen box (IVIS-200TM, Xenogen, Caliper
Life Sciences,). Animals were given the substrate D-luciferin
potassium salt by intraperitoneal injection of 150 mg/kg in
Dulbecco’s phosphate buffered saline and then were anes-
thetized with 1–3% isoflurane gas. Ten min after the D-
luciferin injection, mice were placed onto the warmed stage
inside the light-tight camera box with continuous exposure
to 1–2% isoflurane gas. Imaging acquisition time was from
1 s to 1 min, depending on the bioluminescence signal.
Imaging and quantification of signals were obtained using
the acquisition and analysis software Living Image V. 2.50
(Xenogen Corp.). To measure the intensities of the emit-
ted light, the regions of interest (ROIs) were drawn over the
emitted region of target signal (total p/s/cm2/sr).
Real-time quantitative PCR (qPCR)
Total RNA was extracted from cells using RNAeasy (QI-
AGEN). cDNA was generated using SuperScript II (Invit-
rogen). The relative levels of mRNAs were determined by
qPCR using Cyclophilin mRNA for normalization. Real-
time qPCR was carried out using CFX96 Touch™ Real-
Time PCR Detection System (Bio-Rad). Each PCR was
performed in triplicate with the following profile: the first
cycle at 95◦C for 5 min, then 40 cycles at 95◦C for 15 s and
finally 60◦C for 1 min (i.e. two-step protocol). Primer se-
quences of the tested genes are available upon request.
DNA fiber assay
DNA Fiber assays were performed according to the pre-
viously published protocols (21) with the following modi-
fications using the manufacturer’s protocol (Genomic Vi-
sion, France). In brief, asynchronous exponentially growing
cells were labeled sequentially with the thymidine analogues
IdU and CldU for 30 min each. At the end of the CldU
pulse, cells were harvested by trypsinization and embed-
ded in low-melting agarose plugs. High molecular weight
DNA was isolated using FiberPrep® DNA Extraction Kit
(Genomic Vision) from cells embedded in agarose by brief
heating to 75◦C to melt the agarose followed by agarose di-
gestion. The DNA molecules stretched uniformly and irre-
versibly attached to a treated glass coverslip (CombiCov-
erslips, Genomic Vision) using the FiberComb® molecu-
lar combing system (Genomic Vision) for immunostaining
and fluorescence microscopy. The DNA samples on cov-
erslip were blotted with primary antibodies mouse anti-
BrdU (IdU) (BD Biosciences, Cat#347580) and rat anti-
BrdU (CldU) (Abcam, Cat#AbC117-7513), followed by
goat anti-rat Cy5 (Abcam ab6565) and goat anti-mouse
Cy3.5 (Abcam ab6946) secondary antibodies. Origin firing
efficiency was determined by counting the fraction of new
initiation events––labeled as green only (initiated during the
IdU period) or green-red-green (initiated during the IdU pe-
riod and ongoing in the CIdU period)––among all tracks.
Replication elongation efficiency was determined by mea-
suring the mean length of second-label replication tracks in
double-labeled tracks to analyze active/ongoing fork rates.
Three replicate from each samples were analyzed. A total of
250–450 replication tracks were measured in each sample.
Statistical analysis
Data are presented as mean ± S.D. Sample numbers (N val-
ues represent independent biological samples) and experi-
mental repeats are indicated in the figure legends. Statisti-
cal significance was determined using Student’s t-tests and
one- or two-way ANOVAs (GraphPad Prism). P < 0.05 was
considered significant.
RESULTS
Nuclear ITCH expression is upregulated in breast cancer
We used immunofluorescence (IF), immunohistochemistry
(IHC) and immunoblotting (IB) to examine the subcellular
localization of ITCH in the following cultured human nor-
mal and cancerous breast cell lines with differential tumori-
genic and invasive potential: non-tumorigenic mammary
epithelial cells (MCF10A); tumorigenic, but non-invasive
BC cells (MCF-7); and invasive TNBC cells (MDA-MB-
231). MCF10A and MCF-7 cells exhibited low levels of
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Table 1. Quantification of nuclear ITCH levels in indicated BC subtypes and pathohistological grades in TNBC (italicized)
Breast cancer subtype Negative Low Medium High Total P valuea
Luminal A/B 73 17 28 3 121 <0.05
Her2+ 19 6 0 0 25
Triple-negative (TNBC) 16 24 32 64 136
Stage I 6 4 10 13 33 <0.01
Stage II 7 6 5 23 41
Stage III 0 1 5 7 13
Stage IV 0 0 0 2 2
Unknown 3 13 12 19 47
Total 108 47 60 67 282
aP values indicate the relationship between the levels of nuclear ITCH expression and different BC subtypes (top) or clinicopathological grades in TNBC
(bottom).
cytoplasmic and nuclear ITCH expression; in contrast,
MDA-MB-231 cells expressed both cytoplasmic and nu-
clear ITCH (Figure 1A and B). We observed similar re-
sults in additional cell lines: human mammary epithe-
lial (HMLE) and luminal BC (T47D) cells showed weak
cytoplasmic ITCH staining, whereas MDA-MB-157 and
HCC1937 TNBC cells showed both cytoplasmic and nu-
clear expression (Supplementary Figure S1A). To deter-
mine whether ITCH expression varied with BC subtype, we
performed IB on three luminal (MCF-7, T47D, ZR75) and
four basal-like TNBC (Hs578T, MDA-MB-157, SUM1315,
MDA-MB-231) cell lines. We found that ITCH protein
expression, which correlated with mRNA levels (Supple-
mentary Figure S1B), was higher in basal-like TNBC cells
than in luminal cells (Figure 1C). Furthermore, expression
of ITCH was positively associated with expression of N-
cadherin, a marker of metastatic potential, but inversely
with E-cadherin (Figure 1C). Compared to ITCH, expres-
sion of other HECT family proteins (WWP1, Smurf1, and
Nedd4) was elevated but not exclusive to TNBC cells (Sup-
plementary Figure S1C).
To validate our findings in clinical BC specimens, we used
IHC to score nuclear ITCH expression in 282 BC cases of
varying subtypes, including 136 TNBC cases (Figure 1D).
Nuclear ITCH expression was significantly higher in TNBC
than in luminal subtypes (P < 0.05; Table 1). Nuclear ITCH
expression in the 136 TNBC cases also significantly corre-
lated with a histological grade (P < 0.01; Table 1). In ad-
dition, IHC revealed greater nuclear ITCH expression in
lymph nodes containing metastatic BC than in matched pri-
mary BC or normal breast tissue (P < 0.05; Supplemen-
tary Figures S1D and S1E). Altogether, our data present
unprecedented evidence for ITCH nuclear localization in
TNBC and metastatic BC.
AKT1-mediated phosphorylation of ITCH at Ser257 drives
its nuclear translocation
To determine how ITCH sustains nuclear localization in
TNBC, we investigated post-translational protein modifi-
cations, which have been identified as important for the
regulation of nuclear transport (22). In the presence of
cytokines, ITCH is phosphorylated by JNK (c-Jun N-
terminal kinase) (14). In addition, we used PHOSPHO-
NET (http://www.phosphonet.ca), a Web-based kinase pre-
diction tool, to identify IB kinase (IKK) as well as AKT as
potential ITCH kinases. To test whether these kinases phos-
phorylate ITCH in the absence of external stimuli, we used
immunoprecipitation (IP) using specific antibodies to pull
down endogenous JNK, IKK, and AKT from MCF10A,
MCF-7 and MDA-MB-231 cell lysates and tested their ki-
nase activity using recombinant ITCH protein as a sub-
strate. We used IB to confirm pull-down of the relevant ki-
nases (Figure 2A, middle three rows). JNK, IKK and AKT
immunocomplexes from MCF-7 and MDA-MB-231 cells
phosphorylated ITCH at varying degrees (Figure 2A, up-
per two rows). None of the kinase immunocomplexes iso-
lated from non-tumorigenic MCF10A cells phosphorylated
ITCH. Notably, the AKT immunocomplex from MDA-
MB-231 cells, but not MCF-7 or MCF10A cells, strongly
phosphorylated ITCH. The activity of IKK, JNK, and
AKT immunocomplexes was validated using known pep-
tide substrates (IKB, cJun and GSK3, respectively; Fig-
ure 2A, bottom two rows). The phosphorylation status of
each kinase is also indicative of activation; to measure this,
we performed IB of MCF10A, MCF-7, and MDA-MB-231
lysates using relevant phospho-specific antibodies (Figure
2B). Kinase phosphorylation was limited in MCF10A or
MCF-7 cells; in contrast, AKT phosphorylation was ele-
vated in MDA-MB-231 cells (Figure 2B and C). Thus, con-
sidering its elevated endogenous activity in MDA-MB-231
cells, AKT is an outstanding candidate kinase for ITCH. To
verify that ITCH is a direct substrate of AKT, we performed
a kinase assay using a purified recombinant form of ac-
tive AKT1. ITCH was efficiently phosphorylated by recom-
binant AKT1 (Figure 2D). ITCH contains an N-terminal
protein kinase C-related C2 domain, a unique proline-rich
region (PRR), four tandem WW domains, and a C-terminal
catalytic HECT Ub protein ligase domain(13). We used
truncated forms of ITCH as targets and observed that only
ITCH containing the PRR domain (amino acids 252–267)
was phosphorylated; ITCH containing only the HECT or
WW domain was not (Figure 2D). This suggests that the
AKT-mediated phosphorylation site is located in the PRR
domain of ITCH.
Using MALDI-QIT-TOF-based mass spectrometry
(MS) analysis, we identified the Ser (S) 257 residue in
the PRR domain as the only residue phosphorylated by
AKT1 (Supplementary Figure S2A). An Ala (A) sub-
stitution at S257 (S257A) substantially reduced ITCH
phosphorylation by AKT1 (Figure 2E). Using a nuclear
localization signal (NLS) predictor (23), we demonstrated
that S257 was located in the only potential NLS sequence
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Figure 1. Nuclear ITCH is upregulated in basal-like TNBC. (A) Representative IF images of indicated breast cells stained with anti-ITCH antibody (red)
and counterstained with DAPI (blue) for cell nuclei. (B) Anti-ITCH IB of cytoplasmic (C) and nuclear (N) fractions of indicated cells; GAPDH and H3
are C and N controls, respectively. (C) IB of additional luminal and basal-like BC cell lines stained with the indicated antibodies; GAPDH included as a
loading control. (D) Representative IHC images of a subset of BC tumors, showing negative, low, medium, and high ITCH expression levels stained with
anti-ITCH antibody (brown) and counterstained with hematoxylin (blue) for cell nuclei. Arrows indicate ITCH nuclear staining.
(249-KPSRPPRPSRPPPPTPRR-266) within the ITCH
protein. This suggests that S257 phosphorylation confers
the ability of ITCH to translocate to the nucleus. To test
this, we co-transfected wild-type (WT) or S257A ITCH
into cells with a constitutively active form of AKT1
(myristoylated AKT1; myr-AKT1) and compared nuclear
localization capacity. In the absence of myr-AKT1, neither
WT nor S257A ITCH protein translocated to the nucleus.
In the presence of myr-AKT1, WT ITCH translocated to
the nucleus, whereas S257A ITCH did not (Figure 2F). We
confirmed the role of AKT1 in ITCH nuclear translocation
at the single cell level using IF (Supplementary Figure S2B).
To further validate the effects of S257 phosphorylation on
nuclear localization, we generated a phospho (P)-specific
antibody to detect P-S257 ITCH. We used IB to confirm
that the antibody detected AKT-mediated phosphorylation
at S257 of ectopically expressed ITCH (Supplementary
Figure S2C) and endogenous ITCH (Supplementary
Figure S2D). IF using anti-P-S257 ITCH antibodies in BC
cell lines detected the nuclear localization of P-S257 ITCH
protein in MDA-MB-231 cells, but not in MCF10A or
MCF-7 cells (Figure 2G). Consistent with this, IF imaging
of MDA-MB-231 cells expressing GFP-tagged WT or
S257A ITCH revealed that WT but not S257A ITCH had
intense nuclear expression (Figure 2H). Altogether, these
data demonstrate that AKT-mediated phosphorylation of
ITCH at S257 is important for its nuclear localization.
ITCH nuclear translocation is regulated by a PI3K/AKT-
dependent pathway
The fact that abundant epidermal growth factor recep-
tor (EGFR or ErbB1) expression and the highly ac-
tive PI3K-AKT pathway are common and therapeuti-
cally targeted in TNBC (24) prompted us to explore
whether the EGF/PI3K/AKT signaling pathway can mod-
ulate ITCH phosphorylation and nuclear accumulation.
EGF/PI3K/AKT signaling can be blocked by treatment
with Erlotinib (an EGFR tyrosine kinase inhibitor), GDC-
0941 (a pan-PI3K inhibitor), or MK-2206 (a pan-AKT
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Figure 2. Phosphorylation of ITCH at Ser257 by AKT1 is essential for nuclear translocation in TNBC. (A) In vitro kinase assay using indicated recombinant
proteins as substrates for phosphorylation, visualized by autoradiography (Autorad) and Coomassie Brilliant Blue (CBB) staining for loading controls.
(B) IB of indicated cell lysates stained with the indicated antibodies and (C) Quantification of fold-change relative to expression in MCF10A cells. (D and
E) In vitro AKT1 kinase assays using (D) full-length and truncated ITCH proteins (as shown in schematic; not to scale) and (E) WT and S257A ITCH
recombinant proteins as substrates. (F) IB of cytoplasmic (C) and nuclear (N) compartments in HEK293T cells after transient co-transfection with GFP-
WT or GFP-S257 ITCH and Myr-AKT1; GAPDH and Lamin A are C and N controls, respectively. (G–H) Representative IF images of (G) indicated cell
lines stained with anti-P-S257 ITCH antibody (red) and DAPI, and (H) MDA-MB-231 cells transiently transfected with GFP-WT or GFP-S257A ITCH
stained with anti-GFP antibody (green) and DAPI (blue). N = 3 for IF images.
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inhibitor) and evaluated by examining downstream phos-
phorylation of AKT. Using IB analysis, we observed that
high levels of endogenous phospho-ITCH, which correlated
with high phospho-AKT, were reduced by 2-h treatment
with low concentrations of MK-2206 and GDC-0941 and
a high concentration of Erlotinib (Figure 3A, left, and Fig-
ure 3B). Serum starvation led to reduced levels of phospho-
ITCH, again correlating with phospho-AKT, which were
induced by the addition of EGF except when prohibited
by pre-treatment with MK-2206, GDC-0941, or Erlotinib
(Figure 3A, right, and Figure 3B). We confirmed these re-
sults at the single cell level using IF imaging, which showed
that nuclear ITCH staining was reduced in MDA-MB-
231 cells following treatment with MK-2206, GDC-0941 or
Erlotinib. Furthermore, following serum starvation, pre-
treatment with these inhibitors blocked the nuclear translo-
cation of ITCH upon addition of EGF (Figure 3C and D).
Consistent with these findings, we observed the inhibition
of nuclear ITCH expression following treatment with MK-
2206, GDC-0941 or Erlotinib in subcellular fractionation
experiments (Figure 3E and F). These results strongly sug-
gest that the stimulation or inhibition of EGFR to trigger
AKT activation or inhibition may modulate ITCH phos-
phorylation.
ITCH interacts with and specifically ubiquitinates the linker
histone H1.2 at K46
To uncover the role of nuclear ITCH, we isolated and identi-
fied nuclear proteins that specifically bound to ITCH. First,
we performed IP using an anti-ITCH antibody in MDA-
MB-231 cell extracts. We then used liquid chromatogra-
phy coupled with tandem MS (LC−MS/MS) to isolate
the ITCH-associated proteins. Among the highly abundant
proteins that were pulled down by anti-ITCH antibodies,
linker histone protein H1.2 was identified as the most abun-
dant nuclear protein associated with ITCH (Supplementary
Figure S3A). Similar to ITCH, H1.2 protein expression was
elevated in basal-like TNBC cell lines (Figure 4A) and cor-
related with mRNA levels (Supplementary Figure S3B). We
next used an in vitro Ubn assay containing human Ub E1
Enzyme and Ubch7 E2 Enzyme (19) to determine whether
H1.2 protein is ubiquitinated by ITCH (Figure 4B). IB of
GST-tagged H1.2 revealed a specific high-molecular weight
ladder characteristic of poly-Ub chains within two minutes
(Figure 4B, top); no laddering was observed using GST
alone as a control substrate (Figure 4B, bottom). Omission
of Ub protein from the reaction prevented laddering (Fig-
ure 4B, top), which confirmed the high-molecular weight
species as H1.2-Ub. In vitro Ubn assay clearly demonstrated
H1.2 to be ITCH’s direct Ubn substrate. We then used
transient transfection to show that co-expression of ITCH
with histone H1.2 resulted in H1.2-Ub only in cells co-
transfected with myr-AKT (Figure 4C). In the presence of
truncated ITCH mutants containing only the PRR, WW, or
HECT motifs, H1.2 was not ubiquitinated (Supplementary
Figure S3C). The RING finger family of E3 ligases, cIAP1
and cIAP2, did not catalyze H1.2 Ubn (Figure 4C). These
data identify linker histone protein H1.2 as a specific sub-
strate of ITCH.
Of the seven lysine residues and potential Ubn sites in
H1.2 (25), K46, K63, K64 and K86 residues are conserved
in both human and mouse. We found that K46 was critical
for H1.2 poly-Ubn by ITCH, as a K-to-R single substitu-
tion at K46 (K46R-H1.2) completely abolished H1.2-Ub, as
did the absence of Ub for WT-H1.2 (Figure 4D). H1.2 Ubn
by ITCH at K46 was further verified using Ni-NTA agarose
beads to pull down His-Ub followed by Western blot analy-
sis against H1.2 under completely denaturing conditions in
vivo (Supplementary Figure S3D). In addition, H1.2 poly-
Ubn by ITCH was found be dependent on Ub-K48 and Ub-
K63 (Figure 4E). To investigate the direct effects of H1.2
K46-Ubn on chromosome binding, we used pull-down as-
says to assess binding of HA-tagged WT or K46R H1.2 pro-
teins, before and after Ubn by ITCH, to nucleosomes. Pu-
rified HA-tagged WT H1.2, but not K46R H1.2, was effi-
ciently polyubiquitinated by ITCH. Prior to Ubn by ITCH,
both proteins showed equivalent basal binding to nucleo-
somes; after Ubn, WT H1.2, but not K46R H1.2, exhibited
increased binding affinity for nucleosomes (Figure 4F). The
results indicated that ITCH-mediated K46-Ubn is essential
for the binding of histone H1.2 to chromatin.
ITCH-mediated H1.2 K46 Ubn suppresses RNF168/RNF8-
dependent 53BP1 foci
Poly-ubiquitinated histone H1 serves as an important sig-
naling intermediate for stimulating the hierarchical se-
quence of RNF8/RNF168-mediated DDR events at DNA
damage sites for 53BP1 foci formation following ionizing
radiation (IR) (11). Therefore, we next evaluated whether
53BP1 foci was affected by ITCH and ITCH-mediated H1.2
K46-Ubn (Figure 5). Surprisingly, 53BP1 foci formation
was found significantly more evident after ITCH knock-
down in shITCH cells than in shControl cells prior to IR
exposure. Compared to shControl cells, shITCH cells ex-
hibited severely impaired cell cycle progression (data not
shown). Both H2AX and RNF168 foci were also signif-
icantly elevated in cells expressing shITCH, with no signifi-
cant differences in RNF8 foci formation between groups (P
< 0.05; Figure 5A and B). After IR exposure, the formation
of RNF8, RNF168, 53BP1 and H2AX foci was signifi-
cantly elevated in shITCH cells compared to shControl cells
(P < 0.01; Figure 5A and B). Unlike ITCH knockdown,
before IR, single RNF168 or RNF8 knockdown exerted
no significant effects in 53BP1 foci formation (P < 0.01;
Figure 5C and D). We also assessed whether the height-
ened formation of 53BP1 foci shITCH cells was RNF168-
or RNF8-dependent by examining 53BP1 foci formation in
MDA-MB-231 cells after knockdown of ITCH in combi-
nation with RNF8 or RNF168 knockdown. The formation
of accumulated intrinsic 53BP1 foci in shITCH cells before
IR was significantly abolished by simultaneous RNF168
knockdown, but was unaffected by simultaneous RNF8
knockdown (P < 0.001; Figure 5C and D, two left pan-
els). After IR, however, RNF8 and RNF168 knockdown al-
most completely suppressed IR-induced 53BP1 foci in both
shControl and shITCH cells (P < 0.001; Figure 5C and D,
two right panels). Taken together, these data suggest that
ITCH deficiency-induced 53BP1 foci accumulation is de-
pendent on RNF168 and RNF8.
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Figure 3. ITCH nuclear translocation is mediated through an EGF/PI3K/AKT-dependent pathway. (A and B) IB using the indicated antibodies and (C
and D) IF imaging using anti-ITCH antibody (red) and DAPI counterstain (blue) of MDA-MB-231 cells before and after 12–18 h 1% serum starvation
with or without prior treatment with MK-2206 (0.1 M), GDC-0941 (0.05 M), or Erlotinib (1 M) following the addition of EGF (10 ng/ml). (E and F)
IB of cytoplasmic (C) and nuclear (N) cellular compartments. N = 3. The P values indicate significant differences between the experimental groups treated
with different inhibitors (MK-2206, GDC-0946, or Erlotinib) and the control groups treated with DMSO under normal or serum-starvation conditions
before and after the addition of EGF.
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Figure 4. ITCH interacts with and ubiquitinates linker histone H1.2 at K46. (A) IB of indicated BC cells stained with anti-H1.2 antibodies; GAPDH
included as a loading control. (B) In vitro ITCH-mediated Ubn of bacterially-expressed recombinant GST alone (bottom) or GST-H1.2 (top) in the
absence or presence of ubiquitin. The reaction was terminated at the indicated times and analyzed by IB using anti-GST antibody. (C and D) In vivo
Ubn of H1.2 in HEK293T cells co-transfected with the indicated plasmids. Ubiquitinated HA-tagged H1.2 was IP with anti-HA antibodies followed by
IB with anti-His antibodies for His-tagged Ubn; WT-, K46R-, K63/64R- or K86R-H1.2 mutants. (E) IB using anti-H1.2 antibody to measure in vitro
ITCH-mediated Ubn of GST-H1.2 with WT or Ub mutants in which lysine is mutated to arginine at K63 or K48. N = 3. (F) Pull-down of recombinant
HA-WT or HA-K46R H1.2 proteins –/+ Ub by biotinylated nucleosomes; IB with indicated antibodies. Relative levels of WT and K46R H1.2 binding to
nucleosomes before and after ubiquitination by ITCH, normalized to the pulled down H3 protein levels, are indicated in italics.
In addition, BRCA-1 and RAP80 foci accumulated to
a greater extent in shITCH cells than in shControl cells
(Supplementary Figures S4A and S4B), and depletion of
ITCH resulted in the accumulation of 53BP1 foci in a
BRCA-1 deficient TNBC cell line, HCC1937 (Supplemen-
tary Figures S4C and S4D). We also observed an increase
in H2AX accompanied by ITCH nuclear translocation in
MDA-MB-231 cells after exposure to IR or the chemother-
apeutic drug hydroxyurea (HU) (Supplementary Figures
S4E-S4H). Constitutively high H2AX foci formation in
shITCH cells was further elevated by IR. The H2AX foci
induced by IR or HU decreased in shControl cells within
24 or 4 h after exposure, respectively, but were sustained
in shITCH cells (Supplementary Figures S4E-S4H). In ad-
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Figure 5. ITCH suppresses RNF168/RNF8-dependent 53BP1 foci formation by H1.2 K46 ubiquination. (A, C and E) Representative IF images of MDA-
MB-231 cells, with or without IR exposure (1 Gy, 4 h), using the indicated antibodies against proteins involved in DNA damage and DAPI counterstaining
for nuclei; (B, D and F) Quantification of foci/nucleus in 30 nuclei from each group, data are represented as mean ± S.D., P values compared between
groups indicated with a bracket. (A and B) cells transfected with shITCH for ITCH knockdown or scrambled shRNA control; (C and D) cell transfected
with single or combined shRNA knockdown plasmids against ITCH (shITCH), RNF8 (siRNF8), or RNF168 (siRNF168); (E and F) cells overexpressing
GFP-WT or GFP-K46R-H1.2, N = 3.
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dition to greater accumulation of H2AX foci, we ob-
served greater accumulation of Phospho-ATR (Ser428) and
Phospho-ATM (Ser1981) induced by HU and IR, respec-
tively, in shITCH cells compared to shControl cells (data
not shown). These data strongly indicate that ITCH helps
to suppress the DDR to external damage.
MDA-MB-231 cells after treatment of AKT inhibitor
MK-2206 was able to recapitulate DDR phenotypes of
ITCH knockdown (Supplementary Figure S5). In addition
to reduced nuclear ITCH, significantly elevated 53BP1 and
H2AX foci were found in MDA-MB-231 cells after MK-
2206 treatment. Low but detectable levels of nuclear ITCH
were also found in MCF-7 cells. Only slight changes in the
levels of nuclear ITCH and 53BP1/H2AX foci were ob-
served in MCF-7 after MK-2206 treatment. The results sug-
gest a potential role of nuclear ITCH in the DNA damage
response.
We next investigated whether ITCH-mediated K46 H1.2
Ubn can impact 53BP1 foci formation. MDA-MB-231
cells transgenically overexpressing GFP-tagged WT H1.2 or
Ubn-defective K46R H1.2 were generated (Supplementary
Figure S4I). The average number of intrinsic 53BP1 foci in
individual K46R-H1.2-overexpressing cells was around 4-
fold higher than in WT H1.2-overexpressing cells (P < 0.01;
Figure 5E and F). After IR exposure, 53BP1 foci formation
increased in both cell types, but remained 4-fold higher in
K46R-H1.2 cells than WT-H1.2 cells. RNF168 foci forma-
tion was also elevated in K46R-H1.2 cells to a greater ex-
tent than in WT-H1.2-overexpressing cells prior to and af-
ter IR. These data strongly indicated that ITCH-mediated
H1.2 K46 Ubn is important for preventing 53BP1 accumu-
lation.
ITCH biochemically antagonized RNF168 and RNF8 in
polyubiquitination of histone H1.2
The observation of opposing actions of ITCH and
RNF168/RNF8 on 53BP1 foci formation at the single cell
level (Figure 5) prompted us to examine whether ITCH can
biochemically suppress RNF8/RNF168-mediated H1.2
poly-Ubn. We first assessed the level of H1.2 Poly-Ubn af-
ter ITCH co-transfected with RNF168 or RNF8, along
with WT- or K46R-H1.2 expression plasmids in 293T cells
(Figure 6A). In contrast with cells transfected with ITCH,
RNF168, and RNF8 plasmids, control cells transfected
only with H1.2 showed little to no detectable H1.2 ubiq-
uitination before or after exposure to IR. Prior to IR,
RNF8 did not ubiquinate H1.2. Interestingly, RNF168
ubiquinated WT-H1.2 and to an even greater extent K46R-
H1.2 (Figure 6A, left panel). After IR exposure, RNF8
ubiquitinated WT-H1.2 and to a greater extent K46R-
H1.2. In contrast, basal levels of RNF168-mediated H1.2
Ubn were not significantly elevated by IR (Figure 6A,
right panel). The results suggest that RNF168 is primar-
ily responsible for endogenous H1.2 Ubn whereas RNF8
is primarily responsible for IR-induced H1.2 Ubn. Both
RNF168 and RNF8 elicited higher Ubn levels of K46R-
H1.2 compared to WT-H1.2, suggesting that Ubn of H1.2
by both E3 ligases occurs at a site apart from K46. Most im-
portantly, co-transfection with WT ITCH expression plas-
mids reduced RNF168- and RNF8-mediated H1.2 Ubn
(Figure 6A). The data indicates that ITCH antagonizes
RNF168- and RNF8- mediated H1.2 Ubn.
To confirm the negative relationship between ITCH and
RNF168/RNF8 for H1.2 Ubn, endogenous H1.2 Ubn was
evaluated from MDA-MB-231 cells after knockdown of
ITCH and/or RNF168 or RNF8. shRNA transfection
to knockdown ITCH (shITCH) resulted in elevation of
endogenous H1.2 Ubn compared to transfection with a
scrambled shRNA control (shControl) prior to and after
IR (Figure 6B, left and right panels, respectively). Elevated
H1.2 Ubn induced by ITCH knockdown was reduced sig-
nificantly when combined with RNF168 knockdown prior
to IR (Figure 6B, left panel) or RNF8 knockdown after IR
(Figure 6B, right panel). Re-expressed ITCH reduced the
levels of H1.2 Ubn prior to and after IR in ITCH knock-
down cells. The results strongly suggest the ITCH can neg-
atively regulate RNF168 prior to IR and RNF8 after IR for
H1.2 Ubn.
ITCH makes cells resistant to replication stress and DNA
damage
53BP1 functions as a tumor suppressor that inhibits the in-
vasion and growth of BC cells (26). Persistent 53BP1 foci are
indicative of cells subjected to replication stress and DNA
damage (27). To directly evaluate replication at the single
molecule level, we conducted DNA fiber assays to analyze
incorporation of labeled nucleotides into newly synthesized
DNA fibers after consecutive 30 min pulses of 5-iodo-2′-
deoxyuridine (IdU) and 5-chloro-2′-deoxyuridine (CldU)
(Figure 7A and B). Replication fork progressivity can be
determined by measuring the mean length of CIdU second
pulse-label replication tracks in double-labeled tracks. Rela-
tive CIdU segments were decreased significantly in shITCH
cells compared to shControl cells (Figure 7C). Additionally,
numbers of newly firing origins were reduced in shITCH
cells (Figure 7D). These data strongly suggested that ob-
structed replication fork progression might be resulted from
persistent 53BP1 foci by ITCH knockdown. Alkaline comet
assays, in which the percentage of tail DNA relative to to-
tal DNA is indicative of the levels of DNA damage present
in an individual cell, confirmed the data that DNA damage
was significantly augmented in ITCH knockdown cells or
H1.2 knockdown cells expressing K46R-H1.2 compared to
shControl or H1.2 knockdown cells expressing WT-H1.2,
respectively (Figure 7E and F). RNF168 knockdown in
shITCH cells significantly improved replication fork pro-
gression (Figure 7A-D) and reduced DNA damage (Fig-
ure 7E and F), as well as H2AX foci accumulation (Sup-
plementary Figures S6A and S6B). Furthermore, ITCH
depleted and reconstituted K46R-H1.2 cells (Supplemen-
tary Figure S4J) were sensitized to IR (Supplementary Fig-
ure S7A) and HU (Supplementary Figure S7B) treatment.
Taken together, these data supported the concept that the
ITCH-H1.2 axis confers resistance to replication stress and
DNA damage.
Consistent with this notion, ITCH-mediated K46 H1.2
Ubn may promote cancer growth and metastasis. Thus, we
tested whether disruption of the ITCH-H1.2 pathway limits
cell viability and migration in MDA-MB-231 cells. Trans-
gene S257A ITCH overexpressed in MDA-MB-231cells was
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Figure 6. ITCH biochemically competes with RNF168 and RNF8 to polyubiquitinate histone H1.2. (A) In vivo Ubn of WT- or K46R-H1.2 in HEK293T
cells co-transfected with single or combined GFP-tagged ITCH, Flag-tagged RNF168, or Flag-tagged RNF8 plasmids as indicated, with or without IR
exposure (2 Gy, 4 h). Ubiquitinated DDK-tagged H1.2 was IP with anti-DDK antibodies and detected via IB with anti-His antibodies. (B) IB of Ubn levels
of endogenous H1.2 in MDA-MB-231 after transfection with single or combined scrambled shRNA (shControl), ITCH (shITCH), RNF168 (siRNF168),
RNF8 (siRNF8) knockdown or GFP-ITCH plasmids, with or without IR exposure (2 Gy, 4 h) using Ub antibody after IP with H1.2 antibody. Endogenous
protein levels were examined using the indicated antibodies. N = 3.
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Figure 7. ITCH makes cells resistant to replication stress and DNA damage. (A) MDA-MB-231 cells transfected with single or combined scrambled shRNA
(shControl), ITCH (shITCH), or RNF168 (siRNF168) were labeled consecutively with IdU (red) and CldU (green), for 30 min each, before isolating and
stretching DNA for IF, as illustrated in the schematic. Representative images of dual-labeled fibers are shown. (B) Schematics showing ongoing tracks
sequentially labeled with IdU (red) and CIdu (green). Origin firing events are labeled in green only (initiated during the IdU period) or green-red-green
(initiated during the IdU period and ongoing in the CIdU period). Tracks with stalled/collapsed forks during the IdU period are labeled in red only. The
mean CldU tract length distributions of ongoing tracts (C) and the fold change of new origin firing events defined by these two track types among all labeled
tracks (D) are shown for three independent experiments in which 200–450 tracks/experiments were analyzed for shControl, shITCH, or combined shITCH
and siRNF168 cells. shControl was given an arbitrary value of 1.0. (E) Representative IF images (N = 3) of cell nuclei assessed for single-stranded and
double-stranded breaks using the comet assay at alkaline pH from the agarose-embedded nuclei of MDA-MB-231 cells after transnfection with shControl,
shITCH, or shH1.2 re-expressing WT- or K46R-H1.2 as well as combined shITCH and siRNF168. Cells were stained with SYBR-green after separation
of DNA fragments by electrophoresis. Scale bar, 100 m. (F) Quantification of tail moment detected using comet assays from a total of 90–100 cells in
triplicate were analyzed per group. Data are represented as mean ± S.D.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/2/824/5229214 by U
niversity of Kentucky Libraries user on 07 August 2019
Nucleic Acids Research, 2019, Vol. 47, No. 2 839
also generated (Supplementary Figure S4K). Compared
to shControl, WT ITCH, and WT-H1.2 cells, respectively,
shITCH, S257A ITCH, and K46R-H1.2 cells showed sig-
nificantly reduced colony formation (P < 0.001; Figure 8A
and B), proliferation (P < 0.001; Figure 8C), and invasion
(P < 0.05; Figure 8D and E). To demonstrate the effects of
ITCH knockdown in vivo, we used tumor xenograft mouse
models of MDA-MB-231 cells. shITCH MDA-MB-231 tu-
mors showed significantly reduced growth and invasiveness
relative to shControl tumors (P < 0.001; Figure 8F-I). Thus,
we provide evidence that the ITCH-mediated K46 H1.2 cas-
cade is required for tumor growth and metastatic progres-
sion.
DISCUSSION
Elevated PI3K/AKT oncogenic signaling is considered
a hallmark of carcinomas (17). AKT can be activated
by PI3K or PI3K-like kinase (PIKK) family members:
ataxia-telangiectasia mutated (ATM), ataxia-telangiectasia
and Rad3-related (ATR), and DNA-dependent protein ki-
nase catalytic subunit (DNA-PKcs) (28). In turn, activated
AKT has been shown to be directly involved in inhibition
of homologous-recombination (29) and non-homologous-
end-joining (30) repair pathways to facilitate tumorigenesis.
Our data demonstrate that ITCH serves as a signal trans-
mitter in the EGFR/PI3K/AKT pathway to negatively reg-
ulate RNF168/RNF8-dependent DDR in rapidly replicat-
ing TNBC cells. We showed that nuclear translocation and
S257 phosphorylation of ITCH are induced by IR and HU,
and that IR-induced ITCH and P-S257 ITCH can be re-
duced more efficiently when AKT is inhibited. This sug-
gests that AKT may mediate ITCH nuclear translocation
through PIKK family members after exposure to IR. ITCH
was previously shown to be phosphorylated by ATM kinase
in response to DNA damage (31). The possibility that the
same DNA damage that activates ATM also directly mod-
ulates ITCH nuclear localization cannot be ruled out at this
point.
Following the EGFR/PI3K/AKT pathway, we identify
that H1.2 proteins can be efficiently and specifically ubiqui-
tinated by ITCH at K46. However, the function of ITCH-
mediated H1.2 Ubn at K46 suppressed rather than en-
hanced 53BP1 foci formation. Unlike the RNF8/RNF168-
dependent DDR Ubn of H1.2, which is Ub-K63-specific
(11), ITCH-mediated poly-Ubn of H1.2 was observed to
be Ub-K63- and Ub-K48- dependent. We therefore pro-
pose a hypothesis that ITCH-mediated H1.2 K46 ubiqui-
tination causes the formation of a steric hindrance to pre-
vent full access of RNF8/RNF168. Unlike ITCH using
one E2 UbcH7, H1.2 Ubn by RNF8 was previously shown
to require two E2 enzymes, UBCH5c and UBC13 E2 en-
zymes (11). Additionally, the specific RNF8/RNF168- de-
pendent H1.2 Ubn site was not clearly defined. Clearly
comparing binding affinity to H1.2 between ITCH, RNF8,
and RNF168 and mapping of RNF8/RNF168- dependent
ubiquitination sites will help to understand how ITCH-
mediated K46 Ubn would prevent RNF8/RF68 ubiquity-
lation of H1.2.
Linker histone H1.2 might not be the only ITCH’s
Ubn substrate to regulate DDR. The ITCH-mediated K46
residue in H1.2 is well conserved and identified in related
family members H1.3 and H1.4 (32). Therefore, in addition
to H1.2, Histone H1.3 and H1.4 can be ITCH’s potential
substrates to media DDR. However, the model establish-
ing linker H1 as the target of RNF8 Ubn to mediate IR-
induced 53BP1 foci accumulation has been recently chal-
lenged. L3MBTL2, a putative polycomb group (PcG) pro-
tein, was identified as a key target of RNF8 following DNA
damage (33). The specific sites of DNA damage-induced
RNF8-mediated Ubn have not yet been identified for either
protein. Identification of the Ubn sites will provide valid ev-
idence as specific substrate of RNF8.
We observed that ITCH knockdown caused elevation
of endogenous 53BP1 and H2AX foci formation, which
was dependent on RNF168 but not RNF8. Furthermore,
RNF168 but not RNF8 can efficiently ubiquitinate H1.2 in
the absence of IR. The localization of endogenous 53BP1
and H2AX foci may mark the sites of eroded telom-
eres (34), as well as clustered unrepaired DSB in tumors
(35). The elevation of 53BP1 foci occurred throughout the
genome, including telomeric DNA, and thus may impair
the proliferative capacity of tumor cells. RNF168 has been
shown to directly recruit 53BP1 to DNA damage sites inde-
pendently of the H2AX-MDC1-RNF8 signaling axis (36).
For example, RNF168 can interact with 53BP1 in an IR-
independent manner and facilitate the formation of a pro-
tein complex containing RNF168, 53BP1 and MDC1 (36).
Interaction of RNF168 with 53BP1 and its E3 ligase ac-
tivity was shown to be required for the initial recruitment
and retention of 53BP1 to DNA damage sites. It is possi-
ble that the H1.2 Ubn by RNF168 that we observed in this
study may help to recruit the 53BP1/MDC1 protein com-
plex to chromatin. Thus, enhancement of RNF168 binding
and Ubn to H1.2 after ITCH deficiency might increase re-
cruitment and retention of 53BP1 to DNA damage sites and
lead to induction of spontaneous DDR signaling induced
by replication stress
53BP1 functions as a tumor suppressor and plays a crit-
ical role in cell cycle checkpoint and DNA repair activ-
ities. Accumulation of 53BP1 is associated with human
TNBC and BRCA1-related BCs (37) and contributes to
their resistance to poly(ADP-ribose) polymerase inhibitors
(38). These data indicate that loss of 53BP1 accumula-
tion might be a common mechanism for advanced tumors
to evade oncogenic and chemotherapeutic agent-induced
DNA damage stress. We observed that treatment with the
AKT inhibitor MK-2206 reduced nuclear ITCH accumula-
tion and enhanced 53BP1/H2AX foci formation in MDA-
MB-231 cells, but not in MCF-7 cells in which ITCH ex-
pression was very low. Taken together, these data suggest
that ITCH can function as downstream effector of AKT for
controlling the replication stress response and cell growth
and migration via the 53BP1 DNA damage response path-
way. Several ITCH-related HECT family members (e.g.,
Smurf1, Smurf2, WWP1 Nedd4) and their protein sub-
strates (e.g., Notch1, SMAD2, PTEN, p53) are involved in
tumorigenesis (13) and may serve as promising targets for
cancer therapies. ITCH knockdown sensitized MDA-MB-
231 cells to replication stress and slowed cell growth and
migration. The abundance of total and nuclear ITCH pro-
teins appears to be important for MDA-MB-231 cells to
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Figure 8. Disruption of the ITCH-H1.2 pathway limits cell growth and migration in MDA-MB-231 cells. (A) Representative image (N = 3) of clonogenic
assay of MDA-MB-231 cells stably expressing shITCH or shControl; GFP-tagged WT ITCH, S257A ITCH; H1.2 shRNA knockdown reconstituted with
GFP-tagged WT H1.2 or K46R H1.2. Cells were seeded at 500 cells. Colonies were fixed and stained with crystal violet two weeks later. (B) Quantitative
measurement of clonogenic assays in (A) from triplicate experiments. (C) 500 cells from each group were plated in triplicate on day 0 and counted every 48 h.
(D) Representative images of matrigel invasion assays performed in the above cell groups, stained with 0.5% methylene blue. (E) Quantitative measurement
of invasive cells in (D). (F) Representative bioluminescence images of mice (N = 12) taken at the indicated times. Images show tumor growth following
injection of shITCH or shControl MDA-MB-231 cells into the fourth mammary fat pad of NSG mice; (G) Quantitative analysis of tumor bioluminescence
signals over time (n = 12). (H) Representative images of tumor growth in NSG mice (N = 12) at week 6 following xenograft; (I) Time course of tumor
growth in NSG mice. P values compared between groups indicated with a bracket. Data represented as mean ± S.D.
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maintain genome stability and counteract replication stress.
Because low levels of nuclear ITCH protein were found in
MCF-7 and MCF10A cells (Figure 1A and B), ITCH may
not be as important for counteracting replication stress in
these cell types as it is for MDA-MB-231 cells. Indeed, after
siRNA knockdown of ITCH, cytotoxicity was reduced in
MCF-7 cells and nearly absent in MCF10A cells (data not
shown). These data suggest that the effect of ITCH knock-
down may be selective for TNBC cells. Furthermore, de-
pending on the cellular milieu, ITCH may act as a proapo-
totic or prosurvival factor, which may pose a substantial
challenge to drug development. ITCH inhibitors will need
to be specific, selected not only based on its enzymatic cat-
alytic site. We expect that the work presented here will fa-
cilitate the development of specific ITCH inhibitors that
can block AKT-mediated ITCH S257 phosphorylation and
subsequent H1.2 K46 Ubn for a potential cancer treatment
regimen.
For further details regarding Methods used in this work,
see SUPPLEMENTAL DATA.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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